Intellia Therapeutics Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics or view top-rated stocks.

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Intellia Therapeutics.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its earnings results on Thursday, February, 25th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.12. Intellia Therapeutics had a negative net margin of 193.01% and a negative trailing twelve-month return on equity of 40.14%.
View Intellia Therapeutics' earnings history.

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 375.3% and is now trading at $60.46.
View which stocks have been most impacted by COVID-19.

14 analysts have issued 1 year target prices for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $106.00. On average, they anticipate Intellia Therapeutics' stock price to reach $54.67 in the next year. This suggests that the stock has a possible downside of 9.6%.
View analysts' price targets for Intellia Therapeutics or view top-rated stocks among Wall Street analysts.

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

Some companies that are related to Intellia Therapeutics include Ipsen (IPSEY), Quidel (QDEL), Neogen (NEOG), Riot Blockchain (RIOT), Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Aspira Women's Health (AWH), Oxford Immunotec Global (OXFD), Quotient (QTNT), OncoCyte (OCX), Nymox Pharmaceutical (NYMX) and VolitionRx (VNRX).
View all of NTLA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (8.64%), Nikko Asset Management Americas Inc. (8.64%), BlackRock Inc. (8.55%), Price T Rowe Associates Inc. MD (3.59%), Morgan Stanley (1.99%) and Dimensional Fund Advisors LP (1.67%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, John M Leonard, Jose E Rivera and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics.

NTLA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., BlackRock Inc., ExodusPoint Capital Management LP, SG Americas Securities LLC, Dimensional Fund Advisors LP, Engineers Gate Manager LP, and Squarepoint Ops LLC. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, John M Leonard, Jose E Rivera, and Perry A Karsen.
View insider buying and selling activity for Intellia Therapeutics or view top insider-selling stocks.

NTLA stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Federated Hermes Inc., Avidity Partners Management LP, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Jennison Associates LLC, Hitchwood Capital Management LP, and MPM Oncology Impact Management LP.
View insider buying and selling activity for Intellia Therapeutics or or view top insider-buying stocks.

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTLA stock can currently be purchased for approximately $60.46.

Intellia Therapeutics has a market capitalization of $3.57 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

Intellia Therapeutics employs 270 workers across the globe.

The official website for Intellia Therapeutics is www.intelliatx.com.

Intellia Therapeutics is headquartered at 40 Erie Street Suite 130, Cambridge MA, 02139.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]